Nanotechnology for Neurodegenerative Diseases: Recent Progress in Brain-Targeted Delivery, Stimuli-Responsive Platforms, and Organelle-Specific Therapeutics
Authors:
Top Cited Papers
Open Access
- 1 September 2025
- journal article
- review article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 11015-11044
Abstract
Neurodegenerative diseases—including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis—are characterized by progressive neuronal loss and complex pathological mechanisms such as protein aggregation, mitochondrial dysfunction, and neuroinflammation. Conventional therapies offer limited efficacy due to the blood–brain barrier (BBB) and lack of targeted delivery. Nanotechnology has emerged as a transformative strategy for precise brain-targeted treatment. This review summarizes recent advances in nanoparticle-based drug delivery systems, including polymeric nanoparticles, liposomes, inorganic nanomaterials, and biomimetic carriers, highlighting their design features, BBB-penetration mechanisms, and disease-specific applications. Emphasis is placed on stimuli-responsive nanocarriers that react to pH, reactive oxygen species, or enzyme activity, enabling site-specific drug release. Additionally, organelle-targeting strategies—particularly those directed at mitochondria and lysosomes—are explored for their role in subcellular precision therapy. The integration of diagnostic and therapeutic modalities in theranostic nanoplatforms is also discussed. By consolidating preclinical progress and emerging technologies, this review offers insights into the future of nanomedicine in treating neurodegenerative diseases and lays the groundwork for clinical translation.Keywords
This publication has 203 references indexed in Scilit:
- Near Complete Rescue of Experimental Parkinson’s Disease with Intravenous, Non-viral GDNF Gene TherapyPharmaceutical Research, 2008
- Biodistribution of colloidal gold nanoparticles after intravenous administration: Effect of particle sizeColloids and Surfaces B: Biointerfaces, 2008
- Acetylcholinesterase Inhibitors as Disease-Modifying Therapies for Alzheimers DiseaseCurrent Medicinal Chemistry, 2008
- Cathepsin D Is the Main Lysosomal Enzyme Involved in the Degradation of α-Synuclein and Generation of Its Carboxy-Terminally Truncated SpeciesBiochemistry, 2008
- Antiamyloidogenic and Neuroprotective Functions of Cathepsin B: Implications for Alzheimer's DiseaseNeuron, 2006
- Green tea (−)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease modelsHuman Molecular Genetics, 2006
- The blood-brain barrier: Bottleneck in brain drug developmentNeuroRX, 2005
- β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studiesBiochemical Pharmacology, 2003
- Cellular Delivery of Trophic Factors for the Treatment of Huntington's Disease: Is Neuroprotection Possible?Experimental Neurology, 1999
- Acetylcholinesterase promotes the aggregation of amyloid-β-peptide fragments by forming a complex with the growing fibrils 1 1Edited by A. R. FershtJournal of Molecular Biology, 1997